To date, available treatments for sleep disorders in alpha-synucleinopathies are only partially effective, partly due to the limited mechanistic insight into their oetiology and hence, we set to systemically review and to obtain a more comprehensive and critical overview of the role of orexin in sleep in patients with alpha-synucleinopathies. Here, HCRT is linked to synucleinopathy.